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ABSTRACT
The purpose of this review was to investigate the management of oral candidiasis in
HIV/AIDS patients and to evaluate the different guidelines that are available for its
management. To achieve this aim, three objectives were identified: (i) to identify and
report on the different interventions used to manage oral candidiasis, in patients with
HIV/AIDS, (ii) to determine the efficacy of these interventions, and (iii) to provide
guidelines for management. A thorough systematic search of the literature was carried
out and all relevant papers were graded into three levels of evidence (A, B, and C) and
scored for quality according to set criteria.
A number of topical and systemic antifungal medications are used to treat oral
candidiasis in HIV-positive patients. These include the poleyne antibiotics, nystatin and
amphotericin B. Milder episodes of oral candidiasis respond to topical therapy with
nystatin, clotrimazole troches or oral ketoconazole. Fluconazole has been extensively
evaluated as a treatment for candidiasis. With HIV-infection, a cure rate of 82% has
been achieved with a daily oral dose of 50 mg. Fluconazole was found to be a better
choice of treatment for relapsing oropharyngeal candidiasis, resulting in either better
cure rates or better prevention of relapse. Intravenous amphotericin B has been found to
be effective therapy in azole refractory candidiasis where it was shown to be safe and
well tolerated.
Topical therapies were found to be effective treatment for uncomplicated oropharyngeal
candidiasis, however patients relapsed more quickly than those treated with oral
systemic antifungal therapy. Overall, nystatin appears less effective than clotrimazole
and the azoles in the treatment of oropharyngeal candidiasis. With regard to the
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resolution of clinical symptoms, clotrimazole was found to be just as effective as
the azoles, except when patient compliance was poor. Fluconazole-treated patients were
more likely to remain disease-free during the fluconazole follow-up period than with
those treated with other interventions.
Relatively few studies were qualified to address the provision of guidelines for the
management of oral candidiasis in primary health care settings. Most of the studies
found were of moderate and low quality level of evidence. These studies included the
assessment of different guidelines for identification, treatment and dental needs. They
stressed that patients with HN need dentists who will act as primary health care
providers, together with other providers to ensure adequate overall care.
Given the level of interest and importance of candidiasis associated with treatment of
HN -positive patients, it is surprising to find that little high quality research has been
undertaken. As such, it is hoped that this review would provide researchers, oral health
care workers and other health care providers with an overview of the management of
oral candidiasis associated with HN/AIDS.
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OPSOMMING
Die doelstelling van die oorsig was om ondersoek in te stel na die hantering van orale kandidiase in
HIV/AIDS pasiënte asook om die verskillende beskikbare riglyne vir die behandeling daarvan te
evalueer. Ter verwesenliking van hierdie doelstelling is drie doelwitte geïdentifiseer: (i) om die
intervensies wat gebruik word in die hantering van orale kandidiase behandeling te identifiseer, (ii)
om die effektiwiteit van hierdie intervensies te identifiseer en (iii) om op grond hiervan riglyne vir
die hantering voor te stel. 'n Sistematiese literatuursoektog is uitgevoer en alle relevante artikels is
in drie groepe geklassifiseer (A, B en C) op grond van die data kwaliteit.
'n Verskeidenheid topikale en sistemiese antifungale middels word gebruik om orale kandidiase in
HIV-positiewe pasiënte te behandel. 'n Sukseskoers van 82% is met die gebruik van 'n daaglikse
dosis van 50 mg medikament gerapporteer. Fluconazole was die beter keuse van middel vir die
behandeling van terugkerende orofaringeale kandidiase.
Topikale behandeling was effektief in die behandeling van ongekompliseerde orofaringeale
kandidiase, hoewel die kans op terugkeer van die toestand groter was as met die sistemiese middels.
Pasiënte wat met flukonasool behandel is, het 'n groter kans gehad om siektevry te bly vergeleke
met pasiënte op die ander intervensies.
Meeste van die studies was van middelmatige tot lae kwaliteit en gevolglik was dit moeilik om
behandelingsriglyne te stel. Wat egter wel duidelik is, is dat HIV pasiënte primêre mondsorg
benodig wat saam met ander versorging omvattende sorg sal verseker.
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1CHAPTER I
Introduction
Fungi are ubiquitous organisms. They live in soil, water, animals, and human beings. The
earliest exposure to fungi that most humans experience occurs during birth while passing
through the vaginal canal. In human beings, fungi can inhabit a variety of habitats. Yeast,
such as Candida albicans is frequently isolated from the oral cavity. Oral candidiasis has
been recognized as a clinical entity since the time of Hippocrates (Lynch, 1994), who
described it in association with severe underlying disease in his treatise "Epidemics" which
was published in the 4th century BC.
Candida species (Candida spp.) are omnipresent, and certain species, most notably
Candida albicans (Calbicans) are present in the natural flora of humans. These species
routinely inhabit mucosal tissues and skin and co-exist in an innocuous manner as a
saprophytic colonizer or commensal. In times of stress, and when the body's immune
defence systems are compromised and the normal balance altered, these organisms can
emerge as pathogens (Samaranayake, 1992).
Candidiasis is the name used to describe infections caused by yeast species of the genus
Candida. Candida spp. may cause mild superficial mucocutanous infections and rarely,
invasive life-threatening disease. The latter is usually due to invasion by endogenous
colonizing strains of Candida spp. in the presence of lowered host defence mechanisms.
Calbicons is the species responsible for the majority of these infections (Reef and Mayer,
1995). Oral candidiasis is a frequent and early manifestation of disease associated with the
human immunodeficiency virus (HIV) (Samaranayake, 1989) and has been reported in
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2more than 90% of patients with acquired immunodeficiency syndrome (AIDS) (Phelan,
Saltzman, Friendland and Klein, 1987). Candidiasis may occur as a clinical sign and
symptom of HIV (Van Meter, Gallo, Garcia-Rojas, Tan and Silverman, 1994), most
commonly presenting as pseudomembranous candidiasis, erythematous candidiasis, or
angular cheilitis.
Although oral candidiasis can occur at any stage of HIV infection, it is most common in
patients with low CD4 counts (Greenspan, 1994a). Candida infection of the oral cavity in
many cases, is simply treated with topical antifungal agents and the removal of any
predisposing factors (Odds, 1988). Numerous oral and systemic therapeutic agents are used
to treat oral candidiasis. The efficacy, safety and cost effectiveness of the agent must be
considered when prescribing for the treatment of oral candidiasis (Greenspan, 1994a).
The management of oral candidiasis is an important part of the care of an HIV infected
individual. The high frequency of oropharyngeal candidiasis in immunocompromised
patients has led many institutions to develop guidelines for the use of antifungal agents as a
line of treatment. However, few specific recommendations have been made regarding the
management of oropharyngeal candidiasis in patients infected with HIV (Powderly, Mayer
and Pefect, 1999a). The purpose of this study was to investigate, through a systematic
review, the management of oral candidiasis associated with HIV/AIDS.
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3CHAPTER2
2. Literature Review
2.1 Biology of Candida albicans
Candida albicans is frequently found as a commensal in the oral cavity, gastro-intestinal
and vaginal mucosa. Infection is usually endogenous, although cross-infection can occur,
e.g., from mother to baby and from baby to baby. Calbicens exists as a dimorphic yeast
and grows as spherical to oval budding yeast cells (blastospores ), 3-5 to 5-10 microns in
size, or as cylindrical, multinucleated hyphae. Germ-tube formation leading to hyphal
development is considered important to the pathogenesis of candidal infection (Odds,
1988). It is usually present as a harmless asymptomatic commensal but can manifest as a
pathogen. The organism has been described as the most common and serious fungal
pathogen of man (Shepherd, Poulter and Sullivan, 1985).
2.1.1 Taxonomy
At least 20 genera and nearly 90 species of yeasts have been isolated and classified from
human beings. The genus Candida is a collection of about 150 asporgenus yeast species.
They are classified among the fungi imperfecti in the class Deuteromycetes (Shepherd,
Poulter and Sullivan, 1985). Seven Candida spp. are of major medical importance and of
these, Culbicans, Ciropicalis and Cglabrata are the most frequently isolated. The other
pathogenic Candida spp. are Cparpasilosis, Cstellatoidea, Cguilliermondi, Ckrusei and
Cpseudotropicalis. Within the class Deuteromycetes, the distinguishing feature of the
Candida spp. is their ability to form pseudohyphae, the only exception being C.glabrata
(Shepherd, Poulter and Sullivan, 1985).
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4The taxonomic classification of Calbicens remains a subject of great debate as a result of
different morphologic forms of the organism (Lynch, 1994). Cialbicans is antigenically
divided into two groups: A, which it shares with Ctropicalis, and B, which is shared by
Cstellatoidea. Calbicans can be divided into a number ofbiotypes, which are important in
studies of the epidemiology of outbreaks of disease and in clusters of cases in restricted
areas. Certain biotypes may be more virulent than others and spread through hospital units
just as particular Staphylococcal types or Pseudomonas types are known to spread
(Rippon, 1988). The main feature of the genus Candida is the absence of any teleomorphic
forms and the genus is therefore placed in the subdivision Deuteromycotina (see Table 1).
There are a number of techniques described to type Cialbicans strains, and these include
sereotyping, resistogram typing, morphotyping, killer typing, biotyping, immunoblotting,
electrophoretic karyotyping and DNA finger printing. However, it is generally accepted
that none of these methods are ideal (Tsang, Samaranayake, Philipsen, McCullough,
Reichart, Schmidt- Westhausen, Scully and Porter, 1995). The current data indicate that
there are many different sub-strains of oral Calbicons present in HIV -infected patients.
Korting et al., (1988) found biotypes of 61 oral Culbicons isolates from HIV infected
individuals, with or without signs of candidiasis.
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5Table: 1
Classification of the genus Candida (Barnett, Payne and Yarrow, 1990)
Kingdom: Fungi
Division: E umycotina
Subdivision: Ascomycotina
Subdivision: Basidiomycotina
Subdivision: Deuteromycotina
Class: Blastomycetes
Family: Sporoblomycetacea
Family: Cryptococcacea
Genus: Candida
Species: albicans.
Stellenbosch University http://scholar.sun.ac.za
62.1.2 Oral Carriage
Reports of oral carriage of Cialbicans vary greatly in the literature, although most
investigators (Arendrof and Walker, 1980; Odds, 1988; Schmid, Voss and SolI, 1990)
agree that yeasts are commonly found in the oral cavity of healthy people and that a
significant percentage of the species found are Culbicans (Lynch, 1994). The mean
carriage rates of Calbicons for normal people and for patients are 18% and 41%,
respectively. Carriage of yeast is also influenced by age. The highest incidence is
approximately 50% in infants from 1 week to 18 months of age, followed by adults with a
mean carriage rate of 20%. Neonates and children have the lowest carriage rates at 16%
and 9% respectively (Odds, 1988). It is important to note that the isolation of Calbicons or
other Candida spp. from the oral cavity, in the absence of lesions, does not constitute
evidence of clinical candidiasis (Cannon, Holmes, Mason and Monk, 1995).
Healthy subjects who are Candida carriers have approximately 300 to 500 colony-forming
units per ml of saliva (Arendrof and Walker, 1980). The number of colony-forming units
has a diurnal variation, with higher counts in the early morning and late afternoon (Schmid,
Voss and SolI, 1990). The highest numbers of Candida spp. are thought to be present on
the dorsum of the tongue, followed by the palate and buccal mucosa.
2.2 Pathogenesis
Candidiasis is caused primarily by Calbicons and less frequently, by other species, e.g.
C.parpsilosis and C.tropicalis. The disease itself generally takes two forms: superficial
(mucosa) and invasive (disseminated). Calbicons can infect virtually every tissue in the
human body, but by far the most common manifestation of candidiasis are superficial
lesions of the mucosa surfaces (Shepherd, Poulter and Sullivan, 1985). The commensal
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7nature of these organisms implies that the vast majority of oral candidiasis are endogenous
in origin and that eradication of the organism from the human host by antifungal therapy is
difficult. The latter has obvious implications in the management of oral candidiasis,
because maintenance therapy may be required to keep infection at bay, particularly in
immunocompromised patients (Samaranayake, 1992).
Factors which playa role in the transformation of Candida from commensal to pathogen
include hyphal formation, thigmotropism, protease secretion, adherence, and phenotypic
switching. Cialbicans is pathogenic both in the yeast form and in the pseudohyphea form.
Thigmotropism is the ability of the organism to sense and penetrate mucosal surfaces via
intercellular junctions that may be more readily breached (Sweet, 1997). One of the key
pathogenic mechanisms is the secretion of aspartyl proteases, which have a broad
specificity. These enzymes can act as keratinases, which can penetrate orthokeratinized
mucosa. They are also capable of degrading salivary lactoferrin, lactoperoxidase, mucin
and secretory immunoglobulins. The protease activity is lost above pH 5. Candida
overcomes this problem by producing organic acids at the tips of its pseudohyphea there by
acidifying the microenvironment. The selection of phenotypically altered strains may be
enhanced by a phenomenon known as switching which occurs especially in response to
stress. The binding of Calbicons to oral mucosa is the first step in the infectious process.
The adhesion of Cialbicans to the buccal mucosa of HIV positive patients seems to be
enhanced at a time before immunosuppression becomes obvious.
In superficial candidiasis, the histopathological change is a chronic mucositis with the
yeast confined to the stratum corneum. Netrophils can be seen traversing the epithelial
layer from the underlying lamina propria. When the organisms invade visceral tissue,
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8microabcesses are formed. Both yeast and hyphal forms are present. The initial reaction is
neutrophil invasion. Histocytes, giant cells, and epithelioid cells appear early, and the
reaction may take the form of a granulomatous response. In severely immunocompromised
individuals the immune response may be minimal or nonexistent, leaving the abscess
comprised only of candidal organisms and necrotic tissue.
2.3 Clinical presentation
Oral candidiasis can assume a variety of clinical forms and various classification schemes
have been proposed to describe them (Odds, 1988). The most commonly used scheme
divides clinical lesions into three broad categories of acute, chronic, and mucocutaneous.
Acute candidiasis is further subdivided into pseudomembranous and atrophic forms.
Chronic candidiasis includes atrophic and hyperplastic variants. Mucocutaneous
candidiasis can be localized, familial, or syndrome related.
2.3.1 Acute pseudomembranous candidiasis (thrush)
Acute pseudomembranous candidiasis is a disease of the newborn, old and debilitated
persons or those who are medically compromised. This condition is also known
colloquially as thrush. Thrush is often seen in medically compromised patients, particularly
in those infected with the HIV (Marsh and Martin, 1992). It presents as superficial,
confluent fungal colonies or plaques on the oral mucosa. These plaques can be wiped off to
reveal an erythematous, occasionally bleeding base. This clinical sign is useful in
distinguishing acute pseudomembranous candidiasis from leukoplakia, which by
definition, cannot be rubbed off (Lynch, 1994).
The incidence of acute pseudomembranous candidiasis is less than 5% in otherwise healthy
populations. Neonatal colonization initially occurs from a number of sources, including
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9breast-feeding, health care worker's hands, and pacifiers (Lynch, 1994). Commonly
affected areas are the soft palate, oropharynx, tongue, check and gingiva. The symptoms
include tenderness, burning sensation and dysphagia (Flaitz and Hicks, 1999).
2.3.2 Acute atrophic candidiasis
Acute atrophic candidiasis differs from thrush in that the superficial plaques are absent,
with only an erythematous, painful, frequently burning, stomatitis clinically evident
(Lynch, 1994). It is caused by the suppression of the oral bacterial micro flora by broad-
spectrum antibiotics, typically tetracyclines and corticosteroid therapy. There is a
concomitant overgrowth by the oral fungi, in particular, Culbicons. The mucosa of the
tongue and cheeks becomes thin, inflamed and atrophic in appearance (Marsh and Martin,
1992).
2.3.3 Chronic atrophic candidiasis
This condition often called denture sore mouth, or denture stomatitis, is the most common
form of oral candidiasis (Marsh and Martin, 1992). Characteristically, the lesions appear as
an asymptomatic, extremely erythematous mucositis, limited exclusively to the denture-
bearing mucosa.
2.3.4 Candidalleukoplakia ( Chronic hyperplastic candidiasis)
This condition first appears as a white patch (leukoplakia) intraorally, usually on the buccal
mucous membrane near the commissures. Lesions can be extensive, are usually bilateral,
do not have a surface that is easily removed. This condition is important in that 5-11% of
all these lesions have a propensity to become cancerous (Marsh and Martin, 1992).
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The chronic hyperplastic candidal variant in HIV-positive or AIDS patients should be
clearly distinguished from hairy leukoplakia lesions (Samaranayake and Pindborg, 1989).
Indeed, on histopathologic examination candidal hyphea can be demonstrated within the
superficial epithelium of hairy leukoplakia lesion and Candida spp. can be recovered from
its surface (Greenspan, Pindborg and Schiodt, 1990). However, close examination of the
epithelium should enable its differentiation from hyperplastic candidiasis due to the
characteristic histopathologic features (eg. presence of koilocytes) (Greenspan, Pindborg
and Schiodt, 1990).
2.3.5 Angular cheilitis
Angular cheilitis (angular stomatitis) is a disease of multifactorial aetiology, and it may be
infective or non infective in origin (Samaranayake, 1992). It is frequently seen in
association with chronic atrophic candidiasis. Traditionally, the occurrence of angular
cheilitis has been attributed to vitamin B complex deficiency, decreased vertical
dimension, or focal Candidal infection, either alone or in combination (Lynch, 1994).
Clinically the lesions manifest as red, fissured crusts with or without ulceration and could
be accompanied by subjective symptoms of soreness, tenderness burning, or pain (Ohman,
Dahlen and Moller, 1985). Although the infection is generally caused by Candida spp.
and/or Staphylococcus aurius the extent of involvement of the latter organisms in HIV-
induced angular cheilitis remains to be determined.
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2.3.6 Median rhomboid glossitis
Median rhomboid glossitis (central papillary atrophy) represents a unique form of oral
candidiasis, which in the past was considered to be a developmental defect. However, a
high percentage of median rhomboid glossitis lesions show a superficial invasion of
C.albicans. There continues to be debate as to whether Calbicons causes median
rhomboid glossitis or whether it is simply an opportunistic organism that invades tissue
that has been altered through other mechanisms. This tongue lesion is characterized by a
specific location-anterior to the circumvalate papilla, and has a specific shape-rhomboid.
The lesion surface may vary from nodular to fissured to smooth and depapillated.
Typically this lesion is a symptomatic (Flaitz and Hicks, 1999).
2.4 Diagnosis of Oral Candidiasis
As is the case in other infectious disease, confirmation of a clinical diagnosis of oral
candidiasis depends on the laboratory identification of the pathogen by mycologic and/or
histopathologic techniques. Due to a variety of clinical forms of candidiasis a number of
differing specimens such as smears, swabs, imprint samples, salivary samples, oral rinse
samples and biopsy specimens can be taken (Table 2) (Samaranayake and Holmstrup,
1989).
The diagnosis of oropharyngeal candidiasis generally is not difficult to make, as it has
identifiable characteristics on visual examination and can be cultured from scrapings of
oropharyngeal lesions (Powderly, Mayer and Perfect, 1999a). In addition to clinical signs
and symptoms, which are generally sufficient to enable diagnosis, candidiasis may be
confirmed either by a positive potassium hydroxide (KOH) wet mount, Gram-stained
smear, or a cacofluor stain of specimens obtained from the lesion by swabbing or scraping.
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Fungal cultures are rarely necessary to make a diagnosis of oral candidiasis, but they are
helpful if identification of Candida spp. is desired or colony counts are required. Biopsy
specimens of oral lesions may be useful to distinguish certain forms of leukoplakia and
oral herpetic ulcers similar in appearance to certain Candida variants (Powderly, Mayer
and Perfect, 1999a; Reef and Mayer, 1995).
The development of oropharyngeal candidiasis reflects immunologic impairment or
deterioration in the host. In the case of HIV-positive patients, the occurrence of
oropharyngeal candidiasis should trigger questions about the adequacy and effectiveness of
their current antiretroviral treatment regimen and determination of their CD4+ cell counts
and HIV plasma RNA assays. Once assessed and antiretroviral treatment is initiated or
adjusted, an appropriate medication should be selected for treatment of the oropharyngeal
candidiasis. The range of therapeutic options is wide and includes topical applications,
local and systemic therapy with azoles and intravenous therapy with amphotericin B
(Powderly, Mayer and Pefect, 1999a).
Biopsy may be considered appropriate In certain cases to exclude neoplasia and to
diagnose hyperplastic candidiasis definitively. Haematological investigations are also
important to assess any underlying predisposing factors such as deficiency of iron, vitamin
B 12 or folate (Table 2).
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Table 2: Appropriate laboratory investigations for oral candidiasis (Mcintyre, 2001)
Condition Swab Smear Oral rinse Biopsy Blood tests'
Pseudomembranous + + + - -
Erythematous + +(-) + - -
Hyperplastic + +(-) + +(-) +
Candida-associated denture + + + - +
stomatitis
Angular cheilitis + + + - +
Median rhomobiod glossitis + + + +(-) +(-)
·Blood tests include iron, vitamin BIz, folate, and glucose
+: Useful; - not useful; +( -) may be useful
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CHAPTER3
Aim and Objectives
Aim:
The aim of this study was to systematically review the management of oral candidiasis
associated with HW/AIDS.
Objectives:
To achieve the aim of this study three objectives were identified:
Objective 1: To identify all interventions used for topical and systemic treatment of oral
candidiasis.
Objective 2: To compare the efficacy of the different interventions of treatment of oral
candidiasis in HW patients.
Objective 3: To provide guidelines for the management of oral candidiasis in primary
health care settings.
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CHAPTER4
Methodology
4.0 Introduction
The foundation for the evidence-based approach is the systematic literature review, which
differs significantly from the traditional narrative review. Narrative reviews are usually
broad in scope and are often informed and subjective, supporting the author's views.
Reviews by different authorities may arrive at different conclusions, leaving the reader
wondering what the outcome really is. While narrative reviews are useful for providing a
general perspective on a topic and are appropriate for describing the history of a problem
or its management, their selection of studies is subject to bias and the overall conclusions
may not be accurate. On the other hand, systematic reviews use explicit standards for
evidence retrieval, assessment and synthesis. The methodology of the systematic review is
thoroughly documented and reproducible. The strengths of systematic reviews include a
clearly defined question, a comprehensive search strategy, explicit inclusion criteria,
assessment of methodological quality of the included studies, synthesis of the data and a
summery of the results.
The term "overview" is often used to describe a systematic review, whether it is qualitative
or a quantitative. The preparation of a systematic review is a major undertaking, requiring
considerable time and expertise. Traditional reviews of the literature tend to ignore the
variable quality of studies and are therefore unlikely to present a reliable summary. Ideally,
systematic reviews concentrate on studies that provide the strongest evidence. All the
journals were hand-searched for articles. A diagram illustrating the stage of this systematic
review's methods is presented in figure 1.
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Figure: 1 Review methodology
All references identified by search
methods and submissions
n = 2155
Relevance criteria
1. Related directly to the management of oral candidiasis associated with HIV -patients.
2. Research involved only human beings.
3. Involved one or more groups with different intervention.
4. Related to the efficacy of different intervention of treatment.
..
Did not meet,.. ..
relevance criteria
Met relevance criteria
~
n = 587
Excluded
n = 1568
,
Inclusion criteria
1. English
2. Humans
3. Oral Candidiasis
4. HIV Patients
5. Intervention / Management / Treatment
Exclusion criteria
1. Non English
2. Animal/Lab Studies
3. Studies related to pathogenisis and
aetiology of candidiasis
Met inclusion
criteria
n=93
Did not met inclusion
criteria
Excluded
n=494
Data
extraction
Analysis
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4.1 Search Strategy
4.1.1. Preliminary search
A preliminary search was undertaken to provide information on available reviews of
candidiasis and management on the effects of candidiaisis in HIV seropositive patients.
The preliminary search was carried out in several stages:
• Identification and collection of reviews of candidiasis.
• Medline search using a methodology filter strategy to identify the scope of systemic
reviews and Meta-analysis literature.
• Due to time constraints and budget pressures, the decision was taken to review the
literature from 1990 to present. A preliminary search indicated that most of the
research that reported on interventions for the management of oral candidiasis in
HIV/AIDS was published during this period.
• The Medline database was searched using Winspirs/Silver platter software, the
MESH words were used are oral candidiasis, management and AIDS. Appropriate
filters and limits were used to limit fields of search that match inclusion criteria for
this review.
4.1.2. Hand search
Hand searching of the Index Medicus was undertaken from August 2001 back to 1990. The
bibliographies of the eligible papers were also searched. The reference list of each
retrieved paper was reviewed for hitherto unretrieved papers. All relevant papers were then
also retrieved and the process repeated. To expand this literature process, any journal
appearing in the reference list was added to a list of journals to be hand searched. The
following journals, which are likely to provide the bulk of the data used in this review were
hand searched to identify any relevant studies for inclusion:
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a. Antimicrobial Agants chemotherapy 1990-2001
b. Clinical Infectious Diseases 1990-2001
c. The Journal of Infectious Diseases 1990-2001
d. AIDS 1990-2001
4.2 INCLUSION CRITERIA
4.2.1. Methodology and Quality criteria
The following methodological issues were considered when assessing studies for inclusion:
patient selection, confounding, and measurement. Study designs are often graded
hierarchically according to their quality, or degree to which they are susceptible to bias.
The hierachy indicates which studies should be given most weight in a synthesis. In this
review, the degree to which each study dealt with the methodological issues was graded
into three levels of evidence. Patient groups that were exposed to medication for
candidiasis may differ in respect to factors other than candidiasis itself. Some of these
differences may be related to the outcomes under investigations (type of candidal disease,
Candida spp. involved, level of immunity etc.) and also confound any observed
relationship and thus should be controlled for in the analysis. Confounding factors are
factors that can cause or prevent the outcome of interest. In the case of management of
candidiasis these are likely to include age, other disease, resistant, pharmacogenetic
factors, socioeconomic status, and level of CD4. Factors likely to modify the effect of
medication on the outcomes, such as type of candidiasis and condition of the patient before
the introduction of medication should also be considered.
A specific set of inclusion criteria for each level was developed so that literature of similar
quality or methodological rigour could be grouped together. The inclusion criteria of 3
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levels A, Band C were developed usmg preVIOUSsystematic reviews as guidelines,
together with guidelines developed by Cochrane-type systematic reviews (Kay and Locker,
1998; McDonagh, Whiting, Bradley, Cooper, Sutton, Chestnutt, Misso, Wilson,Treasure
and Kleijnen, 2000). Quality criteria differed according to the different study design. The
quality criteria in this review was assessed in three levels (A, B, and C) and each paper was
scored for.quality according to set criteria (Kay and Locker, 1998) (see Table 3).
Papers selected for this review were classified as level A where all these criteria were met
and level C, were none was met. Level B articles met some of the quality criteria of level
A, but not all (see Table, 4).
4.3. ASSESSMENT OF PAPERS FOR INCLUSION
4.3.1. Relevance assessment
Decisions about the inclusion of studies were made according to the following
pre-determined criteria related directly to the management of oral candidiasis:
• Research involved only human beings.
• Involved two or more groups of interventions.
• HIV/AIDS studies.
A full report of titles and abstracts found to be relevant to the review were obtained for
assessment for inclusion criteria.
4.3.2. Assessment of papers for inclusion criteria
An inclusion criteria was assessed for each of the objectives separately.
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4.4 Exclusion criteria
• Papers in languages other than English were excluded.
• Animal and/or laboratory studies were excluded.
• Papers involving reviews were excluded.
• Papers looking at other aspects of intervention or management of oral candidiasis
were excluded.
Stellenbosch University http://scholar.sun.ac.za
Table 3: Criteria for assessment
Level A (High quality of evidence) Level B (Moderate quality of evidence) Level C (Low quality of evidence)
• Randomized control study design (RCT), • Non-RCT type study. • Research aim was not clearly defined.
quasi RCT- where there was an experimental • The search aims were clearly defined. • No criteria were given for the inclusion /and/or control group. exclusion of subject.• Criteria were given for inclusion / exclusion• The research aims were clearly defined. of subject. • No control or reference group.
• Criteria were given for inclusion / exclusion
of subject. • The paper did not give details of non- • No numbers of participants were given incompliance rates, drop out. each group.
• The paper gave details for non-compliance The number of participants in each group Paper did not define the outcome measures.rates, or drop out. • •was not given. • The length of follow-up period was not• There was a control, or reference group. • The length of follow-up period was not stated.
• The numbers of participants in each group stated. No comments from the authors on the•were given, clinical significance of the findings.
• The paper defined the outcome measures
objectively.
• The length of follow-up period was stated.
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Table: 4 References and quality levels.
No Authors Study The search Inclusion Details of non- Control, or No of participants Outcome Follow-up. Variations Quality level
design RCT aims exclusion compliance or reference in each group. measures.
clearly defined. criteria drop out rate. group •
1 Graybill et ./ ./ ./ ./ ./ ./ ./ ./ ./ A
aI., 1998
2 Phillips et ./ ./ ./ ./ ./ ./ ./ ./ ./ A
aI., 1998
3 Blomgren et ./ ./ ./ ./ ./ ./ ./ ./ ./ A
aI., 1998
4 Moshi et al., ./ ./ ./ ./ ./ ./ ./ ./ ./ A
1998
5 Wilcox et ./ ./ ./ ./ ./ ./ ./ ./ ./ A
al.,1997
6 Pons et al., ./ ./ ./ ./ ./ ./ ./ ./ ./ A
1997
7 Murrayet ./ ./ ./ ./ ./ ./ ./ ./ ./ A
aI., 1997
8 Barbaro et ./ ./ ./ ./ ./ ./ ./ ./ ./ A
al.,1996
9 MacPhail et ./ ./ ./ ./ ./ ./ ./ ./ ./ A
al.,1996
10 Flynn et al., ./ ./ ./ ./ ./ ./ ./ ./ ./ A
1995
11 Barbaro et ./ ./ ./ ./ ./ ./ ./ ./ ./ A
al.,1995
12 Banting et ./ ./ ./ ./ ./ ./ ./ ./ ./ A
al.,1995
13 Konsberg, ./ ./ ./ ./ ./ ./ ./ ./ ./ A
Axell,1994
14 Cartledge et ./ ./ ./ ./ ./ ./ ./ ./ ./ A
al., 1994
15 Hernandez- ./ ./ ./ ./ ./ ./ ./ ./ ./ A
Sampelayo
et al., 1994
16 Pons et al., ./ ./ ./ ./ ./ ./ ./ ./ ./ A
1993
17 Marriott et ./ ./ ./ ./ ./ ./ ./ ./ ./ A
al.,1993
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CAont'd Table: 4
No Authors Study The search aims Inclusionl Details of non Control, or No of participants Outcome Follow-up Variations Quality level
design RCT clearly defined exclusion compliance or reference group in each group measures
criteria drop out rate
18 Rindum et ,( ,( ,( ,( ,( ,( ,( ,( ,( A
aI., 1993
19 Laine et al., ,( ,( ,( ,( ,( ,( ,( ,( ,( A
1992
20 Redding et ,( ,( ,( ,( ,( ,( ,( ,( ,( A
aI., 1992
21 Stevens et ,( ,( ,( ,( ,( ,( ,( ,/ ,/ A
al.,1991
22 Smith et al., ,( ,( ,( ,( ,/ ,( ,( ,/ ,/ A
1991
23 Koletar et ,/ ,( ,( ,( ,/ ,( ,( ,/ ,/ A
aI., 1990
24 Leen et al., ,( ,( ,( ,( ,( ,( ,( ,( ,( A
1990
25 De Wit et ,( ,( ,( ,( ,/ ,( ,( ,/ ,/ A
al.,1990
26 De Wit et ,/ ,/ ,( ,( ,( ,( ,( ,/ ,/ A
al.,1989
27 Dupont and ,( ,( ,( ,/ ,( ,( ,( ,( ,/ A
Drouhet,
1988
28 Fichtenbaum ,( ,( ,( ,( ,/ ,( ,/ B
et al., 2000
29 Saag et al., ,/ ,( ,( ,( ,( ,( ,( B
1999
30 Plettenberg ,/ ,/ ,/ ,( ,/ ,/ B
et al., 1999
31 Cartledge et ,/ ,( ,/ ,/ ,/ ,/ B
al.,1998
32 Cross et al., ,/ ,/ ,/ ,( ,( ,/ ,( B
1998
33 Hegener ct ,/ ,/ ,/ ,/ ,/ ,/ ,( B
al.,1998
34 Revankar et ,/ ,( ,/ ,/ ,( ,( ,/ B
al.,1998 ,
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Cont'd Table: 4
No Authors Study The search Inclusion Details of non Control or No of participants Outcome Follow-up Variations Quality level
design RCT aims clearly exclusion compliance, or reference in each group measures
defined criteria drop out rates group
35 Cartledge et al., -/ -/ -/ -/ -/ -/ -/ -/ B
1997
-/ -/ -/ -/ -/ -/ -/ B
36 De Wit et al., 1997
-/ -/ -/ -/ -/ -/ -/ B ,
37 Hoppe et al., 1997 i
Tumbarello et al., -/ -/ -/ -/ -/ -/ B
I38 1997
-/ -/ -/ -/ -/ -/ -/ -/ B
39 Phillips et al., 1996
-/ -/ -/ -/ -/ -/ -/ -/ B
40 Dronda et al., 1996
Silverman et al., -/ -/ -/ -/ -/ -/ -/ -/ B i
41 1996
Guennee et al., -/ -/ -/ -/ -/ -/ B
42 1995
-/ -/ -/ -/ -/ -/ -/ B
43 Dios et al., 1995
-/ -/ -/ -/ -/ B
44 Laufen, et al., 1995
Plettenberg et al., -/ -/ -/ -/ -/ -/ B
45 1994
White and Goetz, -/ -/ -/ -/ -/ B
46 1994
-/ -/ -/ -/ -/ -/ -/ -/ B
47 Millon et al., 1994
-/ -/ -/ -/ -/ -/ -/ -/ B
48 Laine,1994
Chavanet et al., -/ -/ -/ -/ -/ -/ -/ B
49 1994
-- ----
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Cont'd Table: 4
NO Authors Study The search Inclusion Details of non Control or No of Outcome Follow-up Variations Quality level
design aims clearly exclusion compliance or reference participants in measures
RCT defined criteria drop out rate group each group
y/ ./ ./ ./ ./ ./ ./ ./ 8
50 Vuffray et al., 1994
./ ./ ./ ./ ./ ./ ./ 8
51 De Wit et al., 1993
Just-Nubling et al., ./ ./ ./ ./ ./ ./ 8
52 1990
Thorsen and ./ ./ ./ ./ ./ ./ 8
53 Marthiesen, 1990
./ ./ ./ ./ ./ 8
54 Hay,1990
Weig and Muller, C
55 2001
Jabra-Risk et al., C
56 2000
Flaitz and Hicks, C
57 1999
C
58 Chowet al., 1999
Powderly et al., C
59 1999:1
Powderly et al., C
60 1999b
Ghannuoum and C
61 Elewski, 1999
C
62 I-lood ct al., 1999
C
63 Hood et al., 1998
C
64 Valdez et al., 1998
C
65 Webb et al., 1998
C
66 Darouiche, 1998
Cartledge et al., C
67 1997
- ----- --------- ---- - -----
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Cont'd Table 4
No Authors Study The search Inclusion Details of non Control or No of Outcome Follow-up Variations Quality level
design aims clearly exclusion compliance or referance participants in measures
ReT defined criteria drop out rate group each group
C
68 Ruhnke et al., 1997
Greenspan and e
69 Shirlaw, 1997
Redding et al., e
70 1997
e
71 Hoppe, 1997
e
72 Glick and Burris,
1997
e
73 Green, 1997
Barry and Brown, e
74 1996
Revankar et al., C
75 1996
MilIus and Martin, C
76 1996
e
77 Maenza et al., 1996
Reef and Mayer, e
78 1995
Chryssanthou et al., e
79 1995
Garcia-Hermosa et e
80 aL,1995
Dewsnup, Stevens, C
81 1994
Van Meter et al., e
82 1994
- - - ------ - - ---_._----- - - -----
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Cont'd Table: 4
No Authors Study The search Inclusion Details of non Control or No of Outcome Follow-up Variations Quality level
design RCT aims clearly exclusionon compliance or reference group participants in measures
defined criteria drop out rate each group
Redding et C
83 al.,1994
Newman et C
84 al.,1994
Greenspan, C
85 1994
Greenspan, C
86 1994b
Cameron et C
87 al.,1993
Sanguineti et C
88 al., 1993
C
89 Glatt, 1993
Vander Bijl C
90 and
Arendorf,
1993
Lewis et al., C
91 1991
C
92 Lucatorto et
al.,1991
Blatchford, C
93 1990
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CHAPTERS
RESULTS
5.1 OBJECTIVE 1: To identify all interventions used for topical and systemic
treatment of oral candidiasis.
5.1.1 Topical and systemic treatment
A total of 14 studies on the effect of antifungal medications on oral candidiasis were found.
Thirteen studies assessing the topical and systemic antifungal agents achieved evidence
level A and one evidence level B. The response and the effect of the topical and systemic
antifugals used in the main analysis were changes in different parameters (clinical cure,
colonization, relapse, sign and symptoms) before and after treatment. Table 5 shows the 14
studies that were included in assessing objective one. In this table, the main differences of
the effect of the topical and systemic antifungal medications are shown. All the studies in
Table 5 show variance (95% Confidence intervals or standard deviations) except one study
which is level B quality of evidence.
Oral candidiasis has traditionally been treated with topical antifungal therapy, such as
nystatin suspension or c1otrimazole troches, nystatin pastilles, or the oral systemic agent
ketoconazole for more persistent or difficult cases (Pons, Greenspan, Debruin and the
Multicenter Study Group, 1993) (Tables 6 and 7). The polyene antibiotics, nystatin and
amphotericin B, bind to sterols present in fungal cell membranes causing membrane
leakage of the cellular contents that lead to cell death (Redding, Farinacci, Smith,
Fothergill and Rinaldi, 1992). Nystatin can be used topically as treatment for thrush and is
available as a suspension or pastille. One or two pastilles (200 000 UI pastille) are
dissolved in the mouth 4-5 times a day. Nystatin oral suspension (100 000 UI ml) is used as
a mouth rinse, with 1-5 ml of the suspension held in the mouth for 1 minute, 4 times a day
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(Greenspan and Shirlaw, 1997). Dosing is 4 times daily and side effects, often mild,
include nausea, vomiting and diarrhea.
Amphotericin B is available as a 100 mg ml suspension and as a 10 mg Lozenge (Fugilin).
The suspension is used as a mouth rinse, 1 ml four times daily, swished around the mouth,
held and then swallowed. Amphotericin B Lozenges are held in the mouth for 15-20
minutes, while they dissolve. It is rarely used to treat thrush because of it's significant
toxicity including fever, vomiting, renal, cardiovascular and neurological toxicity.
The synthetic broad-spectrum antiphenols, the azoles, include ketoconazole and
clotrimazole. These agents exert their fungistatic effect by disrupting synthesis of
ergostrol, which changes membrane permeability. Ketoconazole is given orally once daily
and has been proven effective in the treatment of thrush. Unfortunately it requires an acidic
gastric pH for absorption often lacking in patients with HIV/AIDS thus limiting its
effectiveness. Clotrimazole troches have proven effective and currently is the most
commonly used therapy for thrush associated with HIV infection. It is used only as a
topical medication dissolved in the mouth five times daily. Side effects are minimal, but
compliance can be a problem because of frequency of dosing and the fact that some
patients object to the "gritty" feeling of the troches. Clotrimazole troches contain dextrose,
which may promote dental caries. In addition, patients with HIV/AIDS and symptomatic
xerostomia complain of difficulty in dissolving the intraoral troches. For individuals with
angular cheilitis, topical gels and creams such as sugar-free miconazole oral gels
(Daktarin), nystatin and triamcinolon acetonid cream, 1% clotrimazole cream or 2%
ketoconazole cream can be applied to the lesion 3 times daily. When treating patients who
wear dentures their prosthesis must also be included in the antifungal regimen.
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Miconazole gel applied to the fitting surface 4 times daily can be recommended
(Greenspan and Shirlaw, 1997).
A second generation of azoles or triazoles contains the drug fluconazole. This drug
possesses several properties which makes it well suited to treat thrush. The mechanism of
action is similar to ketoconazole; however, fluconazole is a thousand times more selective
as an inhibitor of fungal cell wall sterol biosynthesis. It is considerably more water-soluble
than the earlier azoles resulting in less protein binding and allowing more unbound drug to
reach the site of infection. It does not require an acidic environment for absorption and
readily crosses the blood brain barrier. Fluconazole is not metabolized by the liver as are
the other azoles, so it reaches systemic circulation largely intact. Its oral bio-availability is
greater than 90% and plasma concentration peak two hours after dosing, the route of
elimination is via urine and, to a lesser extent, through the faeces, largely as an unchanged
drug. Fluconazole has been extensively evaluated as a treatment for thrush. With HN
infection, a cure rate of 82% was reported with a daily oral dose of 50mg (Redding,
Farinacci, Smith, Fothergill and Rinaldi, 1992).
Milder episodes of oral candidiasis may respond to topical therapy with nystatin,
clotrimazole troches or oral ketoconazole. As the patient's immune competence declines,
the severity of disease worsens and recurrences occur at more frequent intervals, systemic
therapy may be necessary. Ketoconazole and clotrimazole are less effective than
fluconazole for the treatment of thrush. Fluconazole has been increasingly relied upon for
the management of thrush. When these preparations are used in tablet or capsule forms,
they may be difficult for patients with an advanced stage of AIDS, to swallow, particularly
when marked dysphagia secondary to candidiasis is already present (Graybill et al, 1998).
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Itraconazole is an azole antifungal agent indicated for the treatment of aspergillosis,
blastomycosis, histoplasmosis and recently it has been approved for use in onychomycosis.
Itraconazole has a broad spectrum of activity in-vitro, including a wide variety of Candida
spp. In addition, it has demonstrated in-vitro activity against Candida spp. that are
fluconazole-susceptible or fluconazole-resistant.
Ketoconazole and itraconazole capsules have been shown to be effective in treating
oropharyngeal candidiasis in AIDS patients. However, absorption may be variable in some
HN -infected patients who have been found to be hypochlohydric. Preliminary clinical
studies in AIDS patients with several episodes of oral candidiasis, have shown that
itraconazole oral solution (100 mg twice daily) produced a 100% clinical cure rate after 6
days of treatment and was more effective than topical therapy with clotrimazole troches.
Ketoconazole was the first oral antifungal drug shown to be effective for the treatment and
prevention of oropharyngeal candidiasis, but it has been largely replaced by fluconazole
for several reasons. In a number of studies comparing fluconazole with ketoconazole,
fluconazole was a better choice for the treatment of relapsing oropharyngeal candidiasis
producing either better cure rates or better prevention of relapse. The doses of fluconazole
were 50 or 100 mg/day, while those of ketoconazole were higher (200 or 400 mg/day).
Various studies suggest that a daily dose of 100 or 200 mg for 2-4 weeks is effective, but
few comparative data are available (De Wit, Doherty, Vroey and Clumeck, 1998).
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Table 5: Intervention for topical and systemic treatment.
No Author Study design No & Characteristics Intervention Results and Comments Quality level
of patients
I Graybill et Open label, third 179 HIV+ patients Itraconazole oral solution (200 179 patients available for efficacy; 97% clinical response
al1998 party -blind clinical mg/daily for 7 days or 14 days); after 14 day ofitraconazole and 87 % after 14 day of
trial. flucanozole tablets, 100 mg/daily for fluconazole. 97.5% instead of95% confidence intervals A
14days. (Cl) of the difference in response rate were used in the
determination of equivalence.
2 Flynn et Randomized double 182 immunocompromised Fluconazole suspension 4 mg/(kg. 91% clinical cure with fluconazole versus 51% with
al.,1995 blind, multicenter. children 5-14 y of age. day) loading dose, then 2 mg/(kg. day) nystatin (P<O.OOI). 76% mycological cure with
for 13 days (n=86); nystatin fluconazole versus II % with nystatin. The difference in A
suspension USP 400,000 units 4 times outcomes were statistically significant (P<O.OOI). There
a day for 14 days (n=73). was no significant difference in the clinical efficacy
between two dosage of fluconazole.
3 Pons et al., Randomized single 334 HIV+ patients with oral Fluconazole 100 mg daily for 14 days 98% of available fluconazole-treated patients and 94% of
1993 blind. candidiasis. (n= 176); clotrimazole (10mg) 5 times available clotrimazole-treated patients were cured or
daily for 14 days (n=158). showed improvement (P= not significant). Fluconazole
was more effective in eradicating Candida from oral flora A
than clotrimazole by the end of therapy (65% versus
48%) (P= 0.005).
4 Redding et Randomized double 24 HIV+ patients with Fluconazole 100 mg tablets once/day 100% clinical cure with fluconazole versus 73% with
al.,1992 blind. thrush. (n= 13), or clotrimazole 10 mg troches clotrimazole; 15% colonization of fluconazole versus
five times/day (n=ll) for 14days. 38% clotrimazole. Non of these differences was A
statistically significant using the Student's t Chi-square
test.
5 Pons et al., Randomized open- 167 HIV+ patients with Fluconazole suspension 100 mg (10 138 patients available for clinical outcome; 87% clinical
1997 label. oropharyngeal candidiasis. ml) once daily for 14 days with 200 cure with fluconazole versus 52% with nystatin (p<.OOI);
mg (20 ml) loading dose on day I mycological eradication of Candida spp. at 14 days was A
(n=83); nystatin 5 ml (500,000 U) 4 60% with fluconazole versus 6% with nystatin (P<.OOI);
times daily for 14 days (n=84). 18% relapse rate with fluconazole versus 44% with
-------
_nystatin at the 4 Week follow up-visit (P<.OOI).
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Cont'd Table: 5
No Author Study design No & Characteristics Intervention Results and comments Quality
of patients level
6 Koletar et Randomized, 39 HIV+ patients and oral Fluconazole 100 mg for 14 day (n= 17); Among 36 available patients, clinical resolution
al.,1990 open-label. candidiasis. clotrimazole troche (10mg) 5 times rates were 100 and 65% respectively (P=O.O18).
daily for 14 days (n=19). Mycological eradication rates were 75 and 20%, A
respectively (P=0.004). Fluconazole treated patients
were disease free during follow-up than those
treated with clotrimazole (P=0.014 at 2 weeks).
After 14 days of therapy, fluconazole was clinically
more efficacious and resulted in significantly better
mycological eradiation than c1otrimazole.
7 De Wit et al., Randomized 40 HIV+ patients and Fluconazole 150 mg daily (n=20) or 37 patients available for clinical evaluation; 75%
1993 open-label trail. oropharyngeal candidiasis. Itraconazole 100 mg once daily for 7 clinically cured, with fluconazole versus 20% with A
days (n=20). (Day 8 and 30 follow up). itraconazole. At follow-up, 30% relapse. The
difference was not significant (Fisher's exact test,
two-tailed test).
8 Smith et al., Randomized III HIV+ patients with ltraconazole 200 mg once a day (n=59) Clinical cure with ketoconazole and itraconazole at
1991 double blind candidiasis or ARC 85 with ketoconazole 200 mg twice a day for 28 I week were not significantly different (82 and
study. OPC, 26 with esophageal days (n=52). 75%, respectively; P=0.4497); however, the A
candidiasis average clinical response rate risen to 93% for each
drug by week 4 (P=0.859). When the mycological
response for all the groups of patients was
combined, this was significantly greater for
ketoconazole than for itraconazole at 7 days (92
and 68%, respectively; (P=0.0028). However, after
4 weeks of therapy there was no significant
difference (85 and 83%) in the ketoconazole and
itraconazole groups; respectively.
9 Hemandez- Randomized 46 HIV+ infants and Fluconazole 3 mg/kg per day (n=24); 88% clinical cure with fluconazole versus 81%
Sampelayo and open label. children 0-14 y of age. ketoconazole 7 mg/kg per day (n=22), with ketoconazole; 71% mycological cure with
the Multicenter duration from 5 to 49 days. fluconazole versus 57% with ketoconazole; 50% of B
Study Group, fluconazole-treated patients versus 41% of
1994 ketoconazole treated patients were treated failures
at 4-week follow-up_ visit. (No variance reported).
10 De Wit et al., Randomized 37 HIV+ patients or patients Fluconazole 50 mglday for 2 -42 days 17 available episodes in fluconazole treated patients
1989 double blind. with AIDS. (n= 18); ketoconazole 200 mg/day for 2 and 16 available episodes in ketoconazole treated
-28 days (n= 19). patients; 100% clinical cure with fluconazole A
versus 75% with ketocoazole (P=.045); 87%
culture negative with fluconazole versus 69% with
ketoconazole (P= Not significant).
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No Author Study
des!gn
No & Characteristics
of patients
Intervention Results and comments I Quality
level
A
II Murray et
al.,1997
Open label,
evaluator-
blinded.
162 immunocompromised
patients (83% with HIV or
ARC).
Itraconazole oral solution (10 mglml) 200 mg
per day for 14 days (n=75); clotrimazole troches
(10mg) 5 times daily (n=74).
149 patients available for efficacy; 77%
clinical response with itraconazole versus
70% with clotrimazole (P= Not significant);
60% mycological cure with itraconazole
versus 32% with clotrimazole (P<.OOI); 53% I A
clinical response plus mycological cure with
itraconazole versus 30% with clotrimazole
(P=.006); 46% of itraconazole versus 60% of
clotrimazole recent relapsed by the 28 day
follow-up visit (P=.I 0).
12 Banting,
Greenhorn,
and McMinn,
1995
Randomized
clinical trial.
650 patients with symptoms
of oral candidiasis.
48 ml nystatin; (100,000 IU/ml) dissolved in
432 ml of distilled water producing 10,000 IU
nystatin ml sol. versus nystatin vaginal lozenge
(100,000 IU/g) dissolve in mouth 3 times daily
for 7 days.
Clinical sign and symptoms were cleared
within 7 days. Nystatin denture soaking
solution was not shown to provide any
additional benefit in this study. The difference
between test and control groups in the rate of
positive smears for Cialbicans over the three
observation period was not statistically
significant (M-H Chi Square =0.021,
P=0.886)
13 Konsberg
and Axell,
1994
Randomized
double blind
controlled
clinical trail.
36 patients with denture
stomatitis.
Miconazole I mg (approximately I mi). A single application of a miconazole denture
lacquer considerably reduces the number of
Cyeasts for a substantial period of time.
Miconazole denture lacquer was statistically
significantly better than placebo (P<O.OOI).
A
14 Blomgren,
Berggren,
and Jontell,
1998
Randomized,
blind study.
71 patients diagnosed with
oral candidiasis.
Fluconazole 50 mglday for 7 days (n=36).
Nystatin 4 times daily for 21 days (n=35).
87% improvement with fluconazole and 80%
with nystatin. 8 patients in fluconazole group
and 12 patients in nystatin group were
exhibited relapse within 6 months. No
statistical difference in the outcome of
treatment was revealed between the two
groups as assessed by clinical scoring.
A
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Table 6: Topical agents available for treatment of oral candidiasis
Drug Forms Strength Use
Nystatin Pastille 200,000 units Dissolve 1-2 pastilles 4 times daily
Nystatin- Powder (for oral use) --- Apply to denture 2-3 times daily
triamcinolone
Nystatin Ointment / cream --- Apply to commisures 3 times daily
Clotrimazole Oral troche 10 mg Dissolve 1 troche 5 times daily
Ketoconazole Cream 2% Apply to commisures 3 times daily
Clotrimazole Cream 1% Apply to commisures 3 times daily
Table 7: Systemic agents available for treatment of oral candidiasis
Drug Forms Strength Use
Ketoconazole Tablet 200mg Once daily
Fluconazole Tablet 100mg Once daily
Itraconazole Capsule 100mg 200 mg daily
Amphotericin B Suspension 100mg 1 ml 4 times daily
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5.1.2 Recurrent and Refractory oral candidiasis
A total of 6 studies on the treatment of recurrent and refractory oral candidiasis were
found. The studies assessed the intervention for treatment achieved evidence level B (n=
5) and level C (n= 1). Table 8 shows the 6 studies that were included in assessing the
intervention for recurrent and refractory oral candidiasis. In this table, the main differences
in the interventions for recurrent and refractory oral candidiasis is shown. Of the 6 studies,
only 3 studies reported variance (95% Confidence intervals or standard deviations - Table
8).
The cause of refractory oral candidiasis in HIV patients is multifactorial and includes
incomplete adherence to the regimen, poor absorption, increase metabolism of drug and
overgrowth of a Candida spp. that is less responsive to therapy. However, the most
commonly cited reason for the development of this disorder is alteration in the structure of
Calbicans that leads to drug resistance.
The development of antifungal agents that could be used to treat HIV -positive patients
with recurrent and, in particular refractory oropharyngeal candidiasis, has gained
considerable interest. The overall tolerability of itraconazole oral solution, the combined
topical and systemic effect of the liquid formulation, and its activity against fluconazole-
refractory disease establish this drug as a primary alternative to intravenous amphotericin
B in the treatment of this disorder. To achieve the most durable effect, itraconazole
requires prolonged administration, perhaps as chronic suppressive therapy, in conjunction
with highly active antiretroviral therapy. However, the potential for drug-drug interactions
with some of the antiretroviral agents used in highly active antiretroviral therapy (HAART)
regimens and the development of recurrent disease, even while receiving chronic
suppressive therapy, remains a concern (Saag, 1999).
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Table 8: Intervention for recurrent and refractory oral candidiasis.
No Author Study design No & characteristics
of_j)_atients
Intervention Results and comments Quality level
B
Saag et al., 1999 Open-label,
multicenter trial.
74 HIV+ patients with
confirmed ope who
failed fluconazole
therapy.
100 mg of Itraconazole oral
solution twice daily (200
mg/day) for 14 days.
74 patients were available for efficacy. 41
(55%) achieved a clinical response with 95%
two-sided confidence intervals indicating a
response range of 43% to 67%. Among the
74 patients, 12 did not have mycologic
assessment data on day 14 or day 28. On day
28, eight (Il %) patients had negative
cultures.
2 I Phillips et al., I Prospective, 136 HIV+ patients Itraconazole solution 200
1996 open label, clinically diagnosed of mg daily dose for 14 days,
intervention. typical followed by suppressive
pseudomembranous therapy.
lesions on oral
examination.
34 patients were available, clinical response
to itaraconazole solution was 65%, response
was complete in 24% and partial in 41% of I B
patients, relapse rate 36% within 2 months
(No variance was reported).
3 Fichtenbaum
al.,2000
et I Multicenter,
prospective.
832 Patients with
advanced HIV infection
36 had confirmed
episode of fluconazole
refractory infection and
35 had oral candidiasis
and 1 had esophageal
candidiasis.
200 mg of fluconazole
daily dose for 14 days.
78% treatment-response for the initial
episode of fluconazole, 54% continued
receiving fluconazole after clinical failure.
The continuous use of fluconazole was
significantly associated with fluconazole
failure when compared with no use (p=.005).
In contrast, there was no significant
association between the intermittent use of
fluconazole and the development of
fluconazole failure (p=.I2). In addition, the
total dose of fluconazole was not
significantly associated with the
devel()pment of refractory infection.
B
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Cont'd Table: 8
No I Author I Study design I No &characteristics of I Intervention
atients
4 I Millon et al., Longitudinal 30 patients, 21 was I 50 mg of fluconazole per
1994 study. confirmed with OPC day. and if no
improvement was
observed within 1 week,
the dose was increased to
100 mg/day.
Results and comments
Fluconazole therapy selected resistance
mutans for which MIC increased with
total dose. This resistance characteristic
is genetically stable after several
cultures. The successive increase in the
MICs of fluconazole suggest that there
were several events or independent
events associated with different targets.
(No variance was reported).
Quality level
B
5 Revankar et al.,
1998
Prospective
randomized
trail.
128 patients with active
thrush
200 mg daily or
intermittent therapy with
fluconazole.
It is suggested that combination of
antiretroviral regimens contammg
protease inhibitor may have little
impact in OPC recurrence rates unless
accompanied by both significance viral
load suppression and a sustained rise in
CD4 cell counts. There was no
statistically significant difference in the
OPC recurrence rate before and after
initiation of HAART (0.52 versus 0.41
episodes per 1l10nth;p= 0.22).
B
6 I Lucatorto et al., I Case report. lOne HIV+ patient with a Fluconazole 200 mg per
1991 thick, white, cheesy day orally with a loading
plaque, characteristic of dose of 200 mg twice daily
oral candidiasis. for 1 day.
The oral mucosa showed no evidence
of candida I infection. The patient was
completely free of oral or pharyngeal I C
pain. (No variance was reported).
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Fluconazole has been widely used in HIV-related candidiasis since its release in 1990.
However, fluconazole-resistant oropharyngeal candidiasis has become a significant
management problem, and it is estimated to occur in approximately 5% of patients with
advanced HIV-disease. Intravenous amphotericin has been effective as a salvage therapy in
azole-refractory candidiasis, but this approach is both inconvenient and associated with
potential toxicities. Experience with itraconaozole capsules for fluconazole-resistant
oropharyngeal candidiasis has been disappointing. Itraconazole shares several
pharmacologic properties with ketoconazole including a requirement for gastric acidity for
optimal absorption, a high degree of protein binding and being lipophilic with limited
penetration of aqueous body fluid compartments, and is equally effective as ketoconazole
in HIV -related mucosal candidiasis (Phillips et al, 1996).
Voriconazole is a new potent broad-spectrum triazole antifungal agent. The synergism of
viroconazole (VRC) and terbinafine (TRB) was studied by Weig and Muller, (2001) using
39 genotypically defined clinical Culbicans isolates that were cross-resistant to
fluconazole, and VRC and serial isolates that gradually developed azole resistance.
Synergy was noticed in 100% of the strains that were resistant to VRC. Antagonism was
not observed. They were able to demonstrate effective synergism between VRC and TRB
in vitro against clinical isolates of Culbicuns from HIV -infected patients.
Recurrent oropharyngeal candidiasis in HIV -infected patient is common. The majority of
the recurrent episodes respond to conventional therapy. However, recurrence of
oropharyngeal candidiasis should be considered a warning sign of possible HIV
progression and prompt a re-evaluation of the patients on highly active antiretroviral
therapy, with determination of viral load and CD4 cell counts (Powderly, Mayer and
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Perfect, 1999a). It is recommended that each episode of oropharyngeal candidiasis be
treated acutely until further data are available, provided that the infection is limited to the
oropharyngeal cavity and the patients CD4 cell count is above 50 cell / mm.' It is
recommended that treatment of recurrence with clotrimazole troches continues for as long
as the drug remains effective. However, the importance of compliance needs to be stressed,
as treatment failure may be due to the patients unwillingness or inability to adhere to the
dosing regimen rather than a true reflection of drug efficacy. When a patients does not
respond or is unable to follow the treatment regimen, an alternative approach must be
adopted (Powderly, Mayer and Perfect, 1999a).
After consideration of the immune status of the patient and any warranted adjustments to
the highly active antiretroviral therapy regimen, the patients past exposure to antifungal
agents and current medications should also be taken into account prior to selection of the
most suitable azoles. Phillips (1996) concluded that itraconazole solution appeared to be an
effective treatment for fluconazole-refractory oropharyngeal candidiasis, and suggested
that it may be active both topically and systemically.
5.1.3 Summary
Objective 1 attempted to assess the effect of antifungal medications on oral candidiasis.
The response and the effect with topical and systemic antifungal used in the main analysis
were of the change in different parameter (clinical cure, colonization, relapse, sign and
symptoms) before and after treatment. For this objective, the quality of studies found was
mainly of a high quality (level A). A large number of studies were excluded because there
were case-studies and therefore did not meet inclusion criteria of being evidence (level B)
or above.
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Antifungal medications do appear to manage oral candidiasis especially among HN-
positive patients (Table 8). Fluconazole is the most effective among others antifungals in
the management of oral candidiasis. Only 3 studies showed 100% clinical cure with
fluconazole. The other studies showed statistically significant positive effect with other
antifungal agents. Most of the studies used a single dose of antifungal agents for a short
period. The relapse rate with topical antifungal among some of the studies was high. The
results suggest that a daily single-dose is effective, but few comparative data are available.
All of the studies shown in Table 8 achieved evidence level B and level C. In one study the
successive increase in the mean inhibitory concentrations of fluconazol suggest that there
were several events or independent events associated with different targets (Millon et al.,
1994). Other studies suggested that a combination of antiretroviral regimens containing
protease inhibitors, may have little impact in oropharyngeal candidiasis recurrence rates
unless accompanied by both significant viral load suppression and a sustained raised in
CD4 cell counts. Intravenous amphotericin B has been effective salvage therapy in azole-
refractory candidiasis, but this approach is both inconvenient and associated with
toxicities. In 3 studies, a common approach to management has been to progressively
increase the dose of fluconazole.
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5.2 Objective 2: To compare the efficacy of the different interventions of
treatment of oral candidiasis in HIV -positive patients.
5.2.1 Comparison of available therapy
A total of 20 studies looking at the effect of antifungal drugs and a comparison of their
actions met the inclusion criteria. Most of these studies treated HW -seropositive patients.
Of these, 12 studies achieved evidence level A, 5 achieved evidence level Band 3
achieved evidence level C. The efficacy of different interventions was compared in the
treatment of HW -positive patients. Table 9 shows level A studies that were included in
assessing the efficacy of different intervention of treatment of oral candidiasis in HW-
patients. In this table, a comparison of different interventions is shown.
In general, topical therapies, especially clotrimazole, are effective treatments for
uncomplicated oropharyngeal candidiasis (mild-moderate clinical symptoms with no
esophageal involvement) although patients treated with topical therapies tend to relapse
more quickly than those treated with oral systemic antifungal therapy. Overall, nystatin
appears less effective than clotrimazole and the azoles in the treatment of oropharyngeal
candidiasis. With regard to the resolution of clinical symptoms, clotrimazole is similarly
effective to azoles, except when patient compliance is poor (Philips et al, 1998).
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Table 9: Comparison of available intervention.
No Authors Study design No & characteristics
of patients
Intervention Results and Comments Quality level
2
3
Koletar et I Randomized
aI., 1990 control trail.
Graybill et
al., 1998
Flynn et al.,
1995
Randomized,
third-party-
blind
multicenter
trial.
Randomized
control trail.
179 HIV+ patients
with OPe.
39 HIV+ patients with
oral candidiaisis.
182
immunocompromised
infants & children
with signs of oral
thrush.
Itraconazole sol. 200 197% clinical response after 14 days of
mg/day for 7 or 14 itraconazole and 87% of fluconazole after 14
days.
Fluconazole tab. 100
mg/day for 14 days.
Fluconazole caps. 100
mg/day for 14 day.
Clotrimazole troche. 10
mg 5 times/day for 14
days.
Fluconazole susp. 2-3
mg/kg per day for 14
days.
Nystatin 400,000 U 4
time's daily for 14
d~y_s.
days, 7 days itraconazole oral solution was
equivalent to fluconazole treatment for 14
days, one half of patients in all three groups
relapsed by 1 month after completion of
treatment. Itraconazole oral solution was well
tolerated and offers an alternative at least as
effective as fluconazole in the treatment of
OPC.
Fluconazole-treated patients were more likely
to remain disease free during follow-up than
those treated with clotrimazole.
Clinical resolution rates were 100 and 65%
respectively.
Fluconazole were more effective than
clotrimazole troches in the treatment of HIV-
infected patients with oral candidiasis.
Clinical cure was demonstrated in 91% of the
subject in fluconazole group and 51% of the
subject in the nystatin group. Fluconazole
susp. was more effective than nystatin in the
treatment of thrush in immunocompromised
children.
A
A
A
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Cont'd Table: 9
No Author Study design No & characteristics Intervention Results and Comments Quality
of patients level
4 Pons et al., Randomized 167 HIV+ patients Fluconazole 100 87% clinical cure with fluconazole and 52% with
1997 control trail. with ope. mg/day for 14 days. nystatin. Fluconazole oral suspension as a systemic
Nystatin susp. 500,000 therapy was more effective than liquid nystatin as a A
U 4 times daily for 14 topical therapy in the treatment of oral candidiasis
days. in HIV+ patients and provided a longer disease free
interval before relapse.
5 Philips et Double-blind 244 HIV+ patients Itraconazole sol. 100 These results showed that in the treatment of ope, I
al., 1998 randomized with ope. mg twice daily for 14 itraconazole oral solution and fluconazole capsule A
control trail. days. at a 100 mg single daily dose for 14 days were
Fluconazole caps. 100 equally effective.
mg once daily for 14
days.
6 Laine et al., Randomized 169 AIDS patients. Fluconazole 100 Endoscopic cure occurred in 91% of patients with
I1992 trial. mg/day or fluconazole and 52% with ketoconazole.
Ketoconazole 200 Fluconazole was associated with significantly, A
mg/day for 15 days. greater rate of endoscopic and clinical cure than
ketoconazole in-patients with AIDS and
C.oesophagitis.
7 Smith et Randomized 111 HIV+ patients. Itraconazole 200 75% clinical response of itraconazole and 82% of
al., 1991 control trail. mg/day or ketoconazole after 1 week, after 4 weeks of A
Ketoconazole 200 mg treatment this had risen to 93% in each group.
twice day for 28 days.
8 DeWit, Randomized 40 HIV+ patients with Fluconazole 150 mg A single dose 150 mg of fluconazole may be a safe,
Goossens, control trail. ope. single dose or effective, and convenient therapy for HIV -positive A
and itraconazo 1e 100 patients with Of'C,
Clurneck, mg/day for 7 days.
1993
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Cont'd table: 9
No Authors Study design No &characteristic Intervention Results and Comments Quality level
of patients
9 Pons et Randomized 334 HIV+ patients Fluconazole 100 mg once This study showed that 5 times daily dosing with
al.,1993 multicenter. with oral candidiasis. daily or Clotrimazole 10 clotrimazole was as effective m achieving
mg 5 time's daily for 14 clinical cure as once daily oral dosing with 100 A
days. mg fluconazole taken for 2 weeks. Fluconazole
was shown to be more effective in eradicating
Candida from the oral pharynx at the end of 2
weeks therapy.
10 Redding Randomized 24 HIV+ patients Fluconazole tabs. 100 mg Fluconazole tablets and clotrimazole troches
et al., control. with thrush. once daily or were effective in treating thrush in-patients with A
1992 Clotrimazole troche. 10 HIV infection. Multiple doses versus once per
mg 5 times/daily for 14 day dosing, however would appeared to favour
days. fluconazole as a choice for this infection.
Il Barbaro Double-blind 123 HIV+ patients. Fluconazole 100 mg once Fluconazole was associated with higher rate of
et aL, randomized daily or Itraconazole 100 endoscopic cure than is itraconazole. A
1995 control trail. mg once daily for 1-2
week.
12 Barbaro Double-blind, 85 HIV+ patients. Fluconazole 3 mg/kg Both fluconazole and itraconazole + flucytosine
et al., multicenter daily. Itraconazole 3 association were efficacious m short-term
1996 placebo- mg/kg day. Flucytosin treatment of oesophageal candidiasis in AIDS A
control. association 100 mg/kg patients.
daily for 2 week. Itraconazole + flucytosine association may
represent an alternative therapeutics regimen for
patients with fluconazole resistant
C.oesophagitis.
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Of the available systemic azoles, ketoconazole was found to be the least effective, and until
recently, fluconazole was considered the most reliable. However, the newer oral
suspension of itraconazole, which avoids the erratic absorption and uncertain bioavilability
associated with prior formulations, seems to be as effective as fluconazole for the treatment
of oropharyngeal candidiasis (Philips et al, 1998). Itraconazole has been shown to be
effective in patients with recurrent or persistence oropharyngeal candidiasis. In the study
by Flynn et aI., (1995) fluconazole was significantly more effective than nystatin for
achieving clinical and mycological cure. In a recent randomized, open-label study ofHIV-
infected patients with oropharyngeal candidiasis, the superiority of fluconazole oral
suspension to nystatin oral suspension was confirmed (pons et al, 1997).
Oral itraconazole was compared with oral ketoconazole in the treatment of HIV -infected
patients with oropharyngeal candidiasis in several studies (Smith et al, 1991; de
Repentigny, Ratelle and the HIV Itraconazole Ketoconazole Project Group, 1996). In a
randomized double-blind study (Smith et aI., 1991) in which a 4-week course therapy with
oral itraconazole was compared with oral ketoconazole, oral itraconazole was better
tolerated than ketoconazole. It combined the beneficial effects of topical application to the
oral mucosa with the systemic availability of the oral drug following absorption, and it was
easier to swallow than capsules or tablets for patients with oropharyngeal candidiasis.
Several studies (Murray et al, 1997; Phillips et al, 1996) conducted on patients with
oropharyngeal candidiasis have demonstrated the efficacy of itraconazole oral solution as
the first line therapy for oropharyngeal candidiasis as well as its effectiveness in patients
with fluconazole refractory oropharyngeal candidiasis. Murray et aI., (1997) compared the
efficacy of troches in immunocompromised patients, the majority of whom had HIV
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infection or AIDS and had received prior antifungal treatment. The clinical response was
not significantly higher among patients treated with itraconazole oral solution versus
clotrimazole troches. Treatment with the former drug produced significantly higher rates of
mycological cure and clinical response. Itraconazole oral solution was associated with a
statistically insignificant lower rate of relapse at the end of the 28-days follow up period. In
addition to its higher efficacy, itraconazole oral solution had the added benefit of a once
daily oral administration, whereas the clotrimazoel troches required dosing five times
daily. In studies by Graybill et al (1998) and Greenspan and Shirlaw (1997), HIV-infected
patients were randomized to itraconazole oral solution for 7 or 14 days or to treatment with
oral fluconazole for 14 days. The majority of patients had received prior antifungal therapy
for treatment of oropharyngeal candidiasis, however, treatment with 7-day course of
itraconazole produced lower rates of mycological cure and lower rates of relapse-free
clinical cure at the end of 28 days follow-up period when compared with the other two
groups.
Impaired gastric acid secretion of HIV-infected patients and those with AIDS, may have
important pharmacokinetic, and hence, clinical implications, as the absorption of
antifungal drugs may be impaired under conditions of achlohydria. The absorption of
ketoconazole is markedly reduced under hypochlorohydric conditions, and as a result,
some patients may actually be suboptimally or inadequately treated, even when high-dose
therapy is administered. The absorption and consequently, the serum concentrations of
azole antifungal agents can also be affected by interactions with a variety of drugs. For
example, the concurrent use of rifampicin can reduce the serum concentrations of
ketoconazole, while the use of ketoconazole can decrease the serum concentrations of
theophylline. The concurrent use of rifampicin, phenytoin, cabamazepine, or phenobarbital
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with itraconazole may reduce the plasma concentrations of itraconazole, possibly leading
to clinical failure or relapse.
Darouiche (1998) reported that because both ketoconazole and itraconazole are potent
inhibitors of the hepatic cytochrome p450 enzyme system, the drug-drug interactions with
these two azole agents are generally similar to co-administration of either azole agents with
other drugs primarily metabolized by the p 450 enzyme system and may result in increased
plasma concentration of the latter drugs, often requiring adjustments in the dosing of those
drugs. For instance, the co-administration of either ketoconazole or itraconazole can
potentially increase the plasma concentrations of cyclosporine (possibly requiring a 50%
reduction in the daily dose of cyclosprine), dioxin possibly requiring a 60% -75% decrease
in the daily dose of digoxine), HIV-protease inhibitors saquinavir, indinavir, nelfinavir,
and ritonavir, phenytoin, some antihistamines (terfanadine and astemaizole), certain
sedatives (midazolam) and cisapride.
Another issue related to the pharmacokinetics of azole antifungal agents is the correlation
between salivary and serum concentrations of these drugs and their antifungal efficacy.
Ketoconazole is reportedly more active in-vitro against Calbicans than fluconazole, and
fluconazole is generally more clinically active in the treatment of oropharyngeal and
esophageal candidiasis. Drugs that achieve high concentrations in the oral cavity and/or
saliva, such as fluconazole, might have a local effect (as is achieved with topical antifungal
agents) in the treatment of oropharyngeal and esophageal candidiasis. The salivary
concentration of fluconazole is considerably higher and more sustained than those of
ketoconazole. The relatively high concentration of fluconazole in saliva can be explained
by the fact that fluconazole has a low degree of protein binding, is relatively hydrophilic
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(with good penetration of saliva), and is largely non-ionized under physical conditions.
Although the mean plasma concentration of fluconazole in healthy subjects were reported
to be virtually identical for the oral suspension and the capsule form, fluconazole oral
suspension achieves higher drug levels at the local site of infection and therefore, may
offer at least some theoretical advantages in the treatment of oropharyngeal candidiasis
(Laufen et al, 1995).
Some cases of oropharyngeal candidiasis treated with oral fluconazole are considered to
represent clinical or mycological failures because of diminished in-vitro susceptibility of
Candida isolates to fluconazole as a result of previous exposure to the drug. It is also
possible that low drug concentration in saliva, in association with diminished salivation,
may playa role in cases of therapeutic failure.
In a study by Garcia-Hermosa et al (1995) conducted on 16 patients with AIDS and
oropharyngeal candidiasis who had been treated with fluconazole for at least 7 days,
salivary drug levels were found to correlate well with the dosage of fluconazole, but not
with the therapeutic response. There was also a poor correlation between the drug
concentration in saliva and those in serum, which was again independent of the clinical
response to treatment. Drug levels in saliva were consistently below the mean inhibitory
concentration (MIes) for patients who failed to respond to therapy. These findings indicate
that the presence of a resistant organism, rather than low salivary concentration of
fluconazole, was the more likely cause of treatment failure.
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5.2.2 Drug-resistance and interaction
The common and long-term use of any drug may promote the development of, or select for
resistant strains and thus complicate therapy. There are three possible ways in which a
patient might acquired resistance (i) a colonizing or infecting organism is initially
susceptible but mutates and becomes resistant, (ii) the patient is colonized or infected with
multiple strains or species and an inherently resistant strain or species is selected, or (iii)
the patient is initially colonized or infected with an inherently resistant species.
Concomitant with the wide spread use of triazoles, in particular, fluconazole, there have
been increasing reports of fluconazole-resistant Cialbicans strains. The likelihood of
resistance development increases when patients are on azoles for an extended period
(Ghannoum and Elewski, 1999).
18 studies carried out to examine different antifungal resistance were found. Of these, 4
achieved evidence level Band 14 achieved evidence level C. The resistance of different
antifungal medications and the treatment of drug-resistance candidiasis were evaluated.
Table 10, shows drug-resistant candidiasis, methods of treatment and Candida isolates in
relation to therapy. The growing incidence of resistance to some of the most widely used
antifungal agents is of particular concern. Currently, there are many effective therapeutic
options for oropharyngeal candidiasis. The newer azole antifungal compounds are
commonly used because of their high rate of efficacy ease of administration and low
toxicity. Fluconazole, the most commonly used newer azole, has been found to be
extremely effective and well-tolerated. As a result, it has been widely used to treat
oropharyngeal candidiasis, both for acute episodes (intermittent therapy) and for
prophylaxis (continuous therapy) (Revankar et aI., 1996).
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Table 10: Drug-resistance and interaction.
No Authors Study design No& characteristics Intervention Improvement No Results and comments Quality
of patients , improvement level
1 Cartledge, Multicenter 26 HIV+ patients with D0870 17 = 65% 9=35% D0870 showed promise in the
1998 study. OPC. Fluconazole 150 treatment of resistant OPC
mg/day Initial and excellent efficacy in B
dose & 25 non-resistant HIV -related
mg/day for 6 candidiasis.
days.
2 Thorsen Randomized 16 HIV+ patients with Fluconazole SO- II= 84% 3 =27% HIV infected patients with
and double-blind ore. 13 patients with 200 mg/day. OPC attained complete or
Mathiesen, study. ketoconazole Ketoconazole partial remission on 50-200 B
1990 resistance OPC. 200 mg/day. mg fluconazole per day
Fluconazole appeared to be a
suitable choice of drug in this
respect.
3 Newman, Descriptive 8 HIV+ patients with Fluconazole 8 = 100% The appropriate prophylactic--
1994 study. mucosal candidiasis. 400-800 use of fluconazole to prevent
mg/day. fungal infection in-patients C
with low CD4 lymphocyte
counts needed to be better
defined.
4 Revankar, Cohort study 50 HIV+ with severe Fluconazole 48 = 96% 2=4% Fluconazole-resistant
1996 immunosuppressed. C.albicans & non-C.albicans
yeast infection were common C
10 patients with advance
immunodeficiency, but
clinical efficacy of
fluconazole remained high.
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Cont'd Table: 10
No Authors Study
design
No & Characteristics
of patients
Intervention Improvement No
improvement
Results and comments Quality
level
5 Dewsnup,
and
Stevens,
1994
Case report. 2 HIV+ patients with
oral thrush
Amphotericin B I 2 = 100%
1 mgl5 ml of 5%
dextrose in
water with
cherry
syrup/dose 4
times daily.
200 mg
Fluconazol daily
previous
treatment.
Oral amphotericin B
in-patients with
resistance thrush
efficacious, safe &
tolerated.
therapy
azoles-
were
well e
6 Hegener, I Pilot study.
et al.,
1998
12 patients suffered I Voironazole 200 I 10 = 83%
from end-stage AIDS mg twice / day.
disease.
2= 17% The efficacy of 200 mg twice
daily in patients with
fluconazole-refractory I B
candidiasis, switching to
voriconazole were effective in
the majority of the patients
after 7 days of therapy.
7 Dupont, I Open study.
Drouhet,
1988
61 HIV+ patients with I Fluconazole 50 I 100%
candidiasis. mg once daily.
The results suggest that
fluconazole is an appropriate
treatment for ope, particularly
in AIDS patients. The efficacy I A
of fluconazole treatment
appeared to be as good as
ketoconazole & better than for
topical agents, with which
patient's compliance is_£oor.
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Although, it is clear from published reports that resistance is associated with prior use of
fluconazole, the risk factors for the development of resistance have been well
characterized. Development of fluconazole resistance has been reported after years of
continuous suppressive fluconazole therapy, after only one month of suppressive therapy,
after multiple courses of intermittent therapy, and after reported exposures to single doses
of fluconazole. It cannot be determined from the available data how best to use oral azoles
in the management of HIV -infected patients to avoid later resistance. Most descriptive
reports of fluconazole resistance have been in patients with advanced immunosuppression
(Maenza et al, 1996).
Recently, the occurrence of oral candidiasis not responsive to fluconazole which has been
related to the emergence of fluconazole resistance strains of Candida and, in particular, of
C.glabrata and C.krusi, have been recorded (Tumbarello et al, 1997).
Predisposing factors for oral infection with fluconazole-resistant Candida spp. showed that
it appears to occur more frequently among patients with some identifiable risk factors, viz.,
previous use of fluconazole therapy, advanced stage of HIV -infection and a high number
of episodes of oral candidiasis in the previous years. Some of these factors are strongly co-
related one to the other (Tumbarello et al., 1997). In addition, regardless of the above-
mentioned factors, the extensive use of fluconazole is the most likely cause for the
emergence and increasing prevalence of fluconazole-resistant Candida spp. as it was found
to be the only independent factor selected by multiple logistic regression analysis. In order
to face the potential risk of the emergence and selection of fluconazole resistant- strains of
Candida in patients with AIDS, it is important to consider carefully the selection of the
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antifungal drug and in particular of fluconazole, for the therapy of mild fungal infection
(Tumbarello et al., 1997).
Vuffray et al., (1994) confirmed and observed the emergence of resistant Calbicans strains
during fluconazole therapy for oropharyngeal candidiasis. They suggested that resistance
was accrued by the initially susceptible Calbicans strain during flucoanzole-exposure.
Clinically, cross-resistance between fluconazole and other azoles might also occur. The
large number of HIV -infected patients at risk for oropharyangeal candidiasis and
oesophageal candidiasis mandates that physicians be aware of the epidemiology and
potential determinants of infection with Calbicens that has decreased susceptibility to
fluconazole resistance (White and Goetz, 1994).
The increased prevalence of Calbicans strains with decreased in-vitro susceptibility to
azoles may substantially reduce the prophylactic and therapeutic effectiveness of these
agents against mucosal candidiasis in HIV-infected patients and necessitate the use of more
complex and toxic therapeutic options. Given the increasing incidence of nosocomial
Calbicans infection and sexual transmission of Culbicans, such decreased susceptibility
could also have substantial import for other patient populations (White and Goetz, 1994).
According to Sanguineti et aI., (1993) physicians must consider resistance in cases of
apparent fluconazole failure, and cautions against the indiscriminant use of this important
drug. The mechanism of resistance remains to be elucidated, but the common long-term
use of fluconazole will certainly result in more frequent recognition of therapeutic failure
due to fluconazole-resistant Culbicuns.
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The epidemiology and clinical significance of fluconazole resistance were assessed by
Revankar et al (1996) in a cohort of HIV-infected patients with recurrent oropharyngeal
candidiasis. Fifty patients were prospectively evaluated using a novel method of detecting
fluconazole resistance with chromogenic media containing fluconazole. Previous
fluconazole use and severe immunosuppression were risk factors for resistance. However,
5 of 26 patients had resistant isolates with no prior fluconazole use, and all were severely
immunosuppressed. Despite the high prevalence of resistance, 48 patients clinically
responded to fluconazole. Fluconazole-resistant Calbicons and non-Calbicans yeast
infections are common in-patients with advanced immunodeficiency, but clinical efficacy
of fluconazole remains high.
The problem of fluconazole resistance seems closely linked to advanced AIDS and the
cumulative dose of azoles, resistance to fluconazole dose not appear to develop during the
shorter courses of therapy used for invasive Candida infections. Microbiologic resistance
of Calbicans and non-Calbicans yeast in oropharyngeal candidasis in HIV positive
patients is common, especially in those of immunosuppression and previous fluconazole
use.
5.2.3 Summary
This objective assessed the efficacy of different interventions of treatment of oral
candidiasis in HIV -positive patients. A number of differences were found. The quality of
studies found was mainly high (level A). All the included studies show a comparison
between two different interventions for the treatment of oral candidiasis in HIV -positive
patients are shown in Table 9.
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It shows that a 100% clinical resolution rate with fluconazole-treated patients was achieved
and that patients were more likely to remain disease-free during the fluconazole follow-up
period than those treated with clotrimazole. Although fluconazole was more effective than
clotrimazole troches in treatment of HIV -infected patients with oral candidiasis, one study
showed that the treatment of oropharyngeal candidiasis with itraconazole oral solution and
fluconazole capsule at 100 mg single daily dose for 14 days are equally effective. Another
showed that itraconazole oral solution is well tolerated and offers an alternative at least as
effective as fluconazole in the treatment of oropharyngeal candidiasis.
Table 9 shows that clinical cure by fluconazole is significantly higher than with
ketoconazole in patients with AIDS and C.oesophagitis. In other studies fluconazole is
associated with a higher rate of endoscopic cure than itraconazole. Table 10shows 7
studies that assess drug-resistance and interaction. The quality of studies were moderate
(level B), low (level C) and only one was of high quality (level A).
The long-term use of any drug promotes the development of resistance. The development
of fluconazole resistance has been reported after years of continuous suppressive
fluconazole therapy. Table 10shows that the efficacy of 200 mg twice daily in patients
with fluconazole-refractory candidiasis, switching to voriconazole were effective in the
majority of the patients after 7 days of therapy. The efficacy of fluconazole treatment
appears to be as good as ketoconazole and better than for topical agents where patient
compliance is poor. Oral amphotericin B therapy in patients with azole resistant thrush was
efficacious, safe and well tolerated.
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5.3 Objective 3: To provide guidelines for the management of oral candidiasis in
primary health care settings.
A total of 9 studies of the suggested guidelines of therapy of oral candidiasis associated
with HN were found. The studies assessed different guidelines for identification,
treatment, dental needs and regimen. Of these, 8 studies achieved evidence level C, and 1
study achieved evidence level A. Oral health care has been an integral part of the
management of HN infection and AIDS since the disease was first identified in the early
1980s. The spectrum of HN -associated opportunistic disease occurring in the oral cavity
propelled oral health care providers to the forefront of patient care. Oral candidiasis was
one of the opportunistic infections in the first reported cases of AIDS (Glick and Burris,
1997).
Oral manifestations have been shown to be reliable markers for immune deterioration and
disease progression to AIDS. Furthermore, many of these oral changes interfere with
daily activities and ultimately, influence the patient's quality of life. It is imperative that
the oral health care providers recognize oral pathologies, diagnose and treat oral lesions
or make appropriate referrals (Glick and Burris, 1997). Oral health needs may directly
influence changes in medical practice. Oral pain, a common complaint among persons
with HN, can result in impaired oral nutritional intake and oral administration of
medications. Oral health care workers may be the first to diagnose the oral manifestations
ofHN.
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Identification of the medications taken by the patient will also help to establish the
medical status of HIV-seropositive patients. Immunocompetent HIV-seropositive patients
may not take any medications, others may be taking medication to prevent or treat
opportunistic disease. As HIV-associated immune deficiency progresses, the number of
medications taken may increase.
Oral lesions such as candidiasis and hairy leukoplakia may be the initial SIgn of
progressive immune deficiency or may be signs of disseminated opportunistic disease.
The dental and periodontal examination for HIV -seropositive patients is the same as for
all patients. Treatment planning considerations may be quite different for HIV-
seropositive immunocompetent patient than from those with mild, moderate or severe
immune deficiency.
Identifying an HIV patient's medication is particularly important because of the potential
for interactions between medications. These include hypersensitivity type reactions and
decreased effectiveness or enhanced activity of some medications when prescribed
together. For example, the antiviral drug didanosin (ddl) may decrease the effectiveness
of ketoconazole, an antifungal drug, and the effectiveness of ketoconazole may be reduce
by rifampin, a drug used to treat tuberculosis. Adverse drug reactions in HIV -infected
individuals are often not predictable. Therefore, as when prescribing any medication for a
patient, the health care worker must be familiar with the known adverse effects of the
medication prescribed. In addition, the patient's primary medical care provider should be
informed of medications prescribed, and instructions to the patients should include the
potential for an adverse side effect when any drug is prescribed.
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It is increasingly recognized that the development of oropharyngeal candidiasis reflects
immunologic impairment or deterioration in the host. In the case of HN -positive
patients, the occurrence of oropharyngeal candidiasis should trigger questions about the
adequacy and effectiveness of their current antiretroviral treatment regimen, if any, and
determination of their CD4 cell counts and HN plasma RNA assays. Once assessed and
antiretroviral treatment is initiated or adjusted, an appropriate medication should be
selected for treatment of oropharyngeal candidiasis episode (powderly et al, 1999b).
The most commonly employed topical applications for the treatment of oropharyngeal
candidiasis are nystatin and clotrimazole. An oral suspension of amphotericin B is also
available, but it is used to a much lesser extent. With regards to oral systemic therapy,
three drugs are commonly prescribed in tablets or capsule for the treatment of
oropharyngeal candidiasis: ketoconazole, itraconazole and fluconazole. While varying
doses and treatment patterns have been employed for these drugs, the most common
approach involves a single daily dose (Darouiche, 1998). Intravenous amphotericin B is
inconvenient and associated with severe dose-limiting toxicity, so it is not routinely used
in the treatment of oropharyngeal candidiasis. However, because resistance to
amphotericin B is extremely rare, it remains the drug of choice for patients with severe or
recurring disease and those with oesophageal involvement (Darouiche, 1998; Flynn et al
and the Multicenter Fluconazole Study Group, 1995). Fluconazole suspension, 6 mg/kg
loading dose followed by 3 mg/kg per day, should be considered as acceptable therapy
for oropharyngeal thrush in immunocompromised children.
Many factors have been found to complicate or confound the treatment of
immunocompromised patients with oropharyngeal or esophageal candidiasis. For
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example, it is difficult to eradicate Candida spp. from mucous membranes because these
organisms constitute the normal oral flora. Therefore, most treatment regimens are
directed at controlling symptoms rather than at eradicating the causative pathogens, an
approach that is reinforced by the fact that most antifungal agents (e.g., the azoles) are
fungistatic rather than fungicidal. In addition, chronic suppressive or intermittent
treatment may foster the development of resistance not only in Calbicans but in non-
albicans strains of Candida as well. Treatment is further impeded by the fact that many
patients are inadvertently under-treated because of impaired absorption or drug
interactions. Traditional antifungal agents such as the topical polyenes and imidazoles
may be satisfactory for the treatment of relatively mild and transient episodes of
oropharyngeal candidiasis (e.g., thrush), the clinical utility of these agents ultimately can
be compromised by numerous encumbrances. Similarly, although ketoconazole has a
long history of use for the treatment of oropharyngeal and esophageal candidiasis,
concerns about potentially serious side effects have favored the use of alternative
antifungal agents instead.
The most optimal results, based on both clinical and mycological criteria, are achieved
with the newer triazole agents. Both fluconazole and itraconazole offer clinical efficacy
at least comparable to that of the traditional topical and oral antifungal agents, together
with a highly favorable mycological cure rate. In some cases, there also appears to be
more prolonged response to treatment and lower relapse rate with these newer
compounds. The recent introduction of novel oral formulations of both itraconazole and
fluconazoel offers an important alternative to traditional oral formulations of antifungal
agents. In addition to addressing the problem of poor absorption of the drug in the
traditional dosing forms, these new formulations deliver high concentrations of the drug
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directly to the site of the infection. Moreover, oral solutions are better tolerated, with
fewer drug-drug interactions and more convenient dosing schedules and are easier to
administer than tablets or capsules to patients with severe oral lesions, restricted oral
intake, or inability to swallow (Darouiche, 1998).
5.3.1 Summary
This objective assessed the guidelines for the management of oral candidiasis in primary
health care settings. Relatively few studies were qualified to address this issue. No
included study specifically provided clear guidelines except for one study which had a
high quality of evidence (level A), all the other studies were of moderate (level B) and
low quality (level C) of evidence. The small number of studies, the differences between
them and their low quality rating, suggests caution when interpreting the results. These
studies included and assessing different guidelines for identification, treatment, dental
needs and regimen. A major weakness generally was the lack of control for any possible
confounding factors, many of which were highlighted by the study author. The high
frequency of candidiasis in HIV-patients has led to many authors to develop protocols to
guide the use of antifungal agents in the treatment of this opportunistic infection.
However, few specific recommendations have been made regarding the management of
candidiasis in patients infected with HIV.
Access to oral health care is an essential need for all patients, particularly for individuals
with complex medical conditions. The oral health care worker and the patient may well
establish a strong relationship of trust particularly when the patient has to come
repeatedly for dental treatment.
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The strong casual link between HIV-infection and development of oropharyngeal
candidiasis would suggest that anyone presenting with symptoms and without other
known risk factors be assessed for risk of HIV-infection. Patients should be educated to
recognize the symptoms of the oral candidiasis variants commonly observed in HIV-
infected patients, as well as other oral conditions associated with HIV -infection, such as
Hairy leukoplakia and Kaposi's sarcoma.
The present goal of therapy is re-evaluation of the patient's antiretroviral therapy and
alleviation of clinical symptoms of oropharyngeal candidiasis. In the HN -infected
patients with oropharyngeal candidiasis exhibiting no oesophageal involvement and with
a CD4+ cell count above 50 cell/mar', topical agents such as clotrimazole troches are
excellent choices for initial treatment. In the patient with esophageal involvement and/or
a CD4+ cell count of 50 cells/mm3 or less, a systemic oral azole may be appropriate. In
HN -infected patients with recurrent candidiasis, acute treatment of each episode is
preferred pending further studies. In recognition of the potential for development of drug
resistance, chronic oral antifungal therapy is not generally recommended except for
patients in whom candidal episodes become frequent and/or severe.
Stellenbosch University http://scholar.sun.ac.za
63
CHAPTER6
CONCLUSIONS
Oral candidiasis is a frequent and early manifestation of HIV infection (Samaranayake
and Holmstrup, 1989) and has been reported in more than 90% of patients with AIDS
(Phelan, Saltzman, Friendland and Klein, 1987). Topical treatment of initial or recurrent
episodes of oropharyngeal candidiasis is appropriate, provided the clinical symptoms are
not severe and there is no risk of esophageal involvement. The oral azoles, which are
effective therapies, could be reserved for use in more serious cases of oropharyngeal
candidiasis. This approach would assist in preventing unnecessary fluconazole exposure
and reducing the incidence of drug-resistant candidiasis. Selection of a particular azole
should be made after consideration of a number of variables, including a patient's
medications, past history of oropharyngeal candidiasis and previous azole exposure,
immune status and general health. In the majority of cases, fluconazole is likely to be the
most suitable candidate, since fewer drug interactions have been demonstrated for this
compound.
The new generation of oral triazole antifungal agents-flucoaznole and itraconazole are an
important advance with respect to both efficacy and safety in the management of candidal
infections. Fluconazole is generally safe and well tolerated and has been shown to
produce a rapid clinical and mycological response. Fluconazole posseses several
properties, which make it well suited to treat thrush. With HIV -infection, a cure rate of
82% was achieved with a daily oral dose of 50 ml (Redding et al, 1992). Ketoconazole
and clotrimazole are less effective than fluconazole for treatment of thrush (Graybill et
aI., 1998). Fluconazol and itraconazole have widespread use, in part because of their ease
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of administration and the lack of toxicity. However, neither drug is the perfect antifungal
agent and both have notable drawbacks.
An emerging problem that has arisen due to fluconazole being more widely used, is the
development of resistance. The judicious use of the azole antifungal drugs is clearly
beneficial to many patients, but indiscriminate or inappropriate use is associated with
increasing antimicrobial resistance. Ketoconazole was the first oral antifungal drug
shown to be effective for the treatment and prevention of oropharyngeal candidiasis, but
it has been largely replaced by fluconazole. Itraconazole has been less thoroughly
evaluated in the setting of HIV -related oropharyngeal candidiasis. Various studies
suggested that a daily dose of 100 mg or 200 mg for 2-4 week is effective, but few
comparative data are available (De Wit et al, 1998).
Treatment of refractory disease remains difficult. At present, the most viable approach
for the treatment of refractory disease, of severe or unresponsive episodes of
oropharyngeal candidiasis, and of patients with deep tissue infections, continues to be
intravenous amphotericin B. It is hoped, however, that the widespread use of effective
antiretroviral agents and therapeutic approaches will greatly decrease the incidence of
severe and/or refractory oropharyngeal candidiasis.
During the course of HIV-disease there is a great demand and need for oral health care.
Oral health care workers can act as a primary health care provider, sharing responsibility
with other health care providers to ensure adequate overall care for HIV -patients. The
vast majority of HIV-patients are asymptomatic and many are unaware of their status.
Oral health care workers should be able to recognize oral manifestations, diagnose, treat
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and make appropriate referrals (Glick and Burris, 1997). Treatment planning for HIV-
seropositive patients may vary. Oral health care workers should be aware that unusual
and adverse drugs reaction and interaction also occurs in HIV-seropositive patients. For
many developing countries (including South Africa), HIV prevention is the only means of
containing the epidemic. Preventive approaches include education, change in behavior
(sexual and drug use) and the use of barrier techniques. Diagnosis of HIV is difficult in
the developing world, where there is little access to laboratory techniques, and the cost of
such assessments are exhorbitant. In such a setting, the evaluation of patients, including
oral findings and oral examination screenings, become useful marker for HIV -AIDS
recognition and diagnosis (Epstein and McCarthy, 1996).
The relationship of oral health to the progression ofHIV disease and the most appropriate
preventive oral health care for HIV -infected individuals remains to be studied. These
studies are likely to further emphasize the importance of oral health care in the
management of patients with HIV infection. Dental treatment for HIV -infected dental
patients should be appropriately planned after a thorough evaluation. Alterations to
policies for the rational use of antifungal agents and appropriate surveillance may be
necessary to recognize and deal with the changing spectrum of candidiasis in the future
(Reef and Mayer, 1995). As the treatment of oropharyngeal candidiasis reflects
immunologic impairment or deterioration in the host, any HIV-infected patients
presenting with symptoms should be assessed for adequacy and effectiveness of
antiretroviral treatment and immunodeficiency status.
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Treatment for refractory disease remains difficult, and in many ways, unsatisfactory. At
present, the most viable approach for the treatment of refractory disease, of severe or
unresponsive episodes of oropharyngeal candidiasis, and of patients with deep tissue
infection continues to be intravenous amphotericin B. Further clinical studies are required
to understand the impact of new antiretroviral treatment and viral loads, the prevalence of
opportunistic infections, and the development of drug resistance.
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